Lab21 Sells SC Labs, Assets Acquired by Selah Genomics | GenomeWeb

NEW YORK (GenomeWeb News) – The Cambridge, UK-based personalized diagnostics company Lab 21 said today that it has sold its lab operations in South Carolina to a new entity formed by existing local Lab21 executives who will launch a new company called Selah Genomics.

The sale of the clinical service lab operations in Greenville and Columbia, which Lab21 has run for three years, will remove a loss-making business from the company's books, but will not impact the company's core strategies in the US market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.